Certolizumab Pegol [certolizumab pegol]
- Terms
-
certolizumab pegovaný
Cimzia
kertolizumab pegol
-
CDP 870
CDP870
Cimzia
A polyethylene-glycolated Fab' fragment of TUMOR NECROSIS FACTOR antibody that binds specifically to TNF-ALPHA and neutralises it in a dose-dependent manner. It also inhibits the production of lipopolysaccharide-induced TNF-ALPHA and IL-1 BETA and is used to treat RHEUMATOID ARTHRITIS and PSORIATIC ARTHRITIS.
- DUI
- D000068582 MeSH Browser
- CUI
- M0507051
- History note
- 2016 (2003)
- Public note
- 2016; CERTILIZUMAB PEGOL was indexed under IMMUNOGLOBULIN FAB FRAGMENTS 2003-2015, POLYETHYLENE GLYCOLS 2003-2015, and under ANTIBODIES, MONOCLONAL, HUMANIZED 2003-2015
Allowable subheadings
- AD
- administration & dosage 12
- AE
- adverse effects 5
- AN
- analysis
- BI
- biosynthesis
- BL
- blood
- CF
- cerebrospinal fluid
- CH
- chemistry
- CL
- classification
- DE
- drug effects
- EC
- economics 1
- GE
- genetics
- HI
- history
- IM
- immunology
- IP
- isolation & purification
- ME
- metabolism 1
- PK
- pharmacokinetics 1
- PD
- pharmacology 10
- PH
- physiology
- PO
- poisoning
- RE
- radiation effects
- TU
- therapeutic use 20
- TO
- toxicity
- UL
- ultrastructure
- UR
- urine